Clinical Trial

Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
ADR-002K is administered to heart failure patients with ischemic heart disease who undergo coronary artery bypass surgery (CABG) to investigate its efficacy and safety.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-23.
Status change: Not Yet Recruiting → Recruiting 2026-06-07
Trial Details
NCT Number NCT07192211
Lead Sponsor Rohto Pharmaceutical Co., Ltd.
Conditions Ischemic Heart Disease
Enrollment 50 participants
Start Date 2026-04-28
Primary Completion 2028-09-30 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-09